B. Riley Comments on biote’s Q3 Earnings (NASDAQ:BTMD)

biote Corp. (NASDAQ:BTMD) – Stock analysts at B. Riley issued their Q3 2025 earnings per share estimates for shares of biote in a research note issued on Thursday, March 13th. B. Riley analyst J. Van. Sinderen forecasts that the company will earn $0.10 per share for the quarter. The consensus estimate for biote’s current full-year earnings is $0.75 per share. B. Riley also issued estimates for biote’s Q4 2025 earnings at $0.10 EPS.

Separately, Craig Hallum decreased their target price on biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday.

biote Trading Up 22.5 %

BTMD opened at $3.76 on Friday. biote has a 1-year low of $3.04 and a 1-year high of $8.44. The stock’s fifty day simple moving average is $4.96 and its 200 day simple moving average is $5.55. The stock has a market cap of $204.31 million, a PE ratio of 14.46 and a beta of 1.07.

Hedge Funds Weigh In On biote

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD acquired a new position in shares of biote in the fourth quarter worth approximately $67,000. Commonwealth Equity Services LLC acquired a new position in shares of biote in the fourth quarter worth approximately $68,000. Public Employees Retirement System of Ohio acquired a new position in shares of biote in the fourth quarter worth approximately $69,000. Intech Investment Management LLC acquired a new position in shares of biote in the fourth quarter worth approximately $71,000. Finally, SG Americas Securities LLC acquired a new position in shares of biote in the fourth quarter worth approximately $76,000. 21.68% of the stock is owned by institutional investors and hedge funds.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.